Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) Operating Margin: 2014-2025

Historic Operating Margin for CytomX Therapeutics (CTMX) over the last 11 years, with Sep 2025 value amounting to -264.43%.

  • CytomX Therapeutics' Operating Margin fell 27673.00% to -264.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.46%, marking a year-over-year increase of 1516.00%. This contributed to the annual value of 18.10% for FY2024, which is 2451.00% up from last year.
  • Per CytomX Therapeutics' latest filing, its Operating Margin stood at -264.43% for Q3 2025, which was down 3,736.51% from -6.89% recorded in Q2 2025.
  • CytomX Therapeutics' Operating Margin's 5-year high stood at 46.41% during Q4 2024, with a 5-year trough of -354.67% in Q1 2022.
  • Over the past 3 years, CytomX Therapeutics' median Operating Margin value was -2.28% (recorded in 2023), while the average stood at -18.34%.
  • As far as peak fluctuations go, CytomX Therapeutics' Operating Margin soared by 33,061bps in 2023, and later tumbled by 27,673bps in 2025.
  • Quarterly analysis of 5 years shows CytomX Therapeutics' Operating Margin stood at -313.54% in 2021, then spiked by 26,629bps to -47.25% in 2022, then spiked by 4,497bps to -2.28% in 2023, then soared by 4,869bps to 46.41% in 2024, then plummeted by 27,673bps to -264.43% in 2025.
  • Its last three reported values are -264.43% in Q3 2025, -6.89% for Q2 2025, and 44.43% during Q1 2025.